Morgan Stanley on Bicycle Therapeutics (BCYC): program deprioritization 'disappointing,' but 'right call'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| (NASDAQ: BCYC) | Delayed: 3.72 +0.05 (1.36%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.67 | 52 Week High | $ | |||
| Open | $3.75 | 52 Week Low | $ | |||
| Day High | $3.80 | P/E | N/A | |||
| Day Low | $3.65 | EPS | $ | |||
| Volume | 215,101 | |||||
